Abstract: This invention relates to the technical field of harmonic elimination for ferromagnetic resonance for a voltage transformer (abbreviated as PT), in particular, to a harmonic elimination method for ferromagnetic resonance for an active resistance-matching voltage transformer based on PID-adjustment, including compiling a resistance matching algorithm; designing and building a harmonic elimination control system based on the PID control strategy; presetting an active resistance-matching strategy; designing an engineering scheme for placing resistors.

Abstract: This invention relates to the technical field of harmonic elimination for ferromagnetic resonance for a voltage transformer (abbreviated as PT), in particular, to a harmonic elimination method for ferromagnetic resonance for an active resistance-matching voltage transformer based on PID-adjustment, including compiling a resistance matching algorithm; designing and building a harmonic elimination control system based on the PID control strategy; presetting an active resistance-matching strategy; designing an engineering scheme for placing resistors.

Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.

Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.

Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.

Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.

Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.

Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.

Abstract: A delivery system for delivering a therapeutic agent to a patient includes a catheter, a stop feature, a container and a bar. The catheter has a proximal end and a distal end and includes a body defining a lumen that extends to the distal end of the catheter. The stop feature is in proximity to the distal end of the catheter. The container is configured to house the therapeutic agent and is insertable and slidably disposable in the lumen of the catheter. The container is also configured to engage the stop feature of the catheter. The bar is slidably disposable in the lumen of the catheter. Sliding of the bar distally in the lumen forces the therapeutic agent out of the container and out of the lumen when the container is engaged with the stop feature. The stop feature is configured to inhibit the container from exiting the lumen.

Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.

Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.

Abstract: A delivery system for delivering a therapeutic agent to a patient includes a catheter, a stop feature, a container and a bar. The catheter has a proximal end and a distal end and includes a body defining a lumen that extends to the distal end of the catheter. The stop feature is in proximity to the distal end of the catheter. The container is configured to house the therapeutic agent and is insertable and slidably disposable in the lumen of the catheter. The container is also configured to engage the stop feature of the catheter. The bar is slidably disposable in the lumen of the catheter. Sliding of the bar distally in the lumen forces the therapeutic agent out of the container and out of the lumen when the container is engaged with the stop feature. The stop feature is configured to inhibit the container from exiting the lumen.

Abstract: A delivery system for delivering a therapeutic agent to a patient includes a catheter, a stop feature, a container and a bar. The catheter has a proximal end and a distal end and includes a body defining a lumen that extends to the distal end of the catheter. The stop feature is in proximity to the distal end of the catheter. The container is configured to house the therapeutic agent and is insertable and slidably disposable in the lumen of the catheter. The container is also configured to engage the stop feature of the catheter. The bar is slidably disposable in the lumen of the catheter. Sliding of the bar distally in the lumen forces the therapeutic agent out of the container and out of the lumen when the container is engaged with the stop feature. The stop feature is configured to inhibit the container from exiting the lumen.

Abstract: Modified and/or derivativized ?-glucans with an enhanced capacity to modulate human immune response as compared to the parent, unmodified and/or underivatized ?-glucans are demonstrated.

Abstract: The method may include administering to a subject in need thereof an effective amount of an HCN polynucleotide. The HCN polynucleotide includes a nucleotide sequence encoding an HCN polypeptide having channel activity. The amino acid sequence of the HCN polypeptide and the amino acid sequence of a reference polypeptide have at least 80% identity, where the reference polypeptide begins with an amino acid selected from amino acids 92-214 and ends with an amino acid selected from amino acids 723-1188 of SEQ ID NO:8. An example of a reference polypeptide is amino acids 214-723 of SEQ ID NO:8. The HCN polynucleotide may be DNA or RNA.

Abstract: The HCN polynucleotide includes a nucleotide sequence encoding an HCN polypeptide having channel activity. The amino acid sequence of the HCN polypeptide and the amino acid sequence of a reference polypeptide have at least 80% identity, where the reference polypeptide begins with an amino acid selected from amino acids 92-214 and ends with an amino acid selected from amino acids 723-1188 of SEQ ID NO:8. An example of a reference polypeptide is amino acids 214-723 of SEQ ID NO:8. The HCN polynucleotide may be DNA or RNA. The HCN polynucleotide may be present in a vector, such as a viral vector (including, for instance, a single strand adeno-associated virus or a self complementary adeno-associated virus), a transposon vector, or a plasmid vector.

Abstract: The method may include administering to a subject in need thereof an effective amount of an HCN polynucleotide. The HCN polynucleotide includes a nucleotide sequence encoding an HCN polypeptide having channel activity. The amino acid sequence of the HCN polypeptide and the amino acid sequence of a reference polypeptide have at least 80% identity, where the reference polypeptide begins with an amino acid selected from amino acids 92-214 and ends with an amino acid selected from amino acids 723-1188 of SEQ ID NO:8. An example of a reference polypeptide is amino acids 214-723 of SEQ ID NO:8. The HCN polynucleotide may be DNA or RNA.

Abstract: The method may include administering to a subject in need thereof an effective amount of an HCN polynucleotide. The HCN polynucleotide includes a nucleotide sequence encoding an HCN polypeptide having channel activity. The amino acid sequence of the HCN polypeptide and the amino acid sequence of a reference polypeptide have at least 80% identity, where the reference polypeptide begins with an amino acid selected from amino acids 92-214 and ends with an amino acid selected from amino acids 723-1188 of SEQ ID NO:8. An example of a reference polypeptide is amino acids 214-723 of SEQ ID NO:8. The HCN polynucleotide may be DNA or RNA.

Abstract: A delivery system for delivering a therapeutic agent to a patient includes a catheter, a stop feature, a container and a bar. The catheter has a proximal end and a distal end and includes a body defining a lumen that extends to the distal end of the catheter. The stop feature is in proximity to the distal end of the catheter. The container is configured to house the therapeutic agent and is insertable and slidably disposable in the lumen of the catheter. The container is also configured to engage the stop feature of the catheter. The bar is slidably disposable in the lumen of the catheter. Sliding of the bar distally in the lumen forces the therapeutic agent out of the container and out of the lumen when the container is engaged with the stop feature. The stop feature is configured to inhibit the container from exiting the lumen.